ONO Pharmaceutical Co., Ltd.

As of March 31, 2025, ONO Pharmaceutical Co., Ltd. carries a market capitalization of 752.81B, placing it among publicly traded companies globally. Its enterprise value stands at 694.86B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

ONO Pharmaceutical Co., Ltd.'s next confirmed earnings release is scheduled for October 29, 2026.

As of March 31, 2025, ONO Pharmaceutical Co., Ltd. has 469.77M shares outstanding.

These figures are as of March 31, 2025.

As of March 31, 2025, ONO Pharmaceutical Co., Ltd. maintains a current ratio of 3.07, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2025.

Over the twelve months ended March 31, 2025, ONO Pharmaceutical Co., Ltd. recorded an income tax benefit of -988.00M rather than an expense, typically from losses, carryforwards, or the release of a tax provision.

As of the close on October 22, 2026, ONO Pharmaceutical Co., Ltd.'s stock has gained approximately 37.03% over the past 52 weeks. The 50-day moving average sits at 2,395.16, while the 200-day moving average is 2,392.34.

As of March 31, 2025, ONO Pharmaceutical Co., Ltd. holds 210.38B in cash and equivalents against 146.68B in total debt, resulting in a net debt position of -69.57B. Total book value stands at 782.45B, with working capital of 306.81B providing operational flexibility.

These figures cover the twelve months ended March 31, 2025.

Over the twelve months ended March 31, 2025, ONO Pharmaceutical Co., Ltd. paid dividends of 2.19 per share.

ONO Pharmaceutical Co., Ltd.'s most recent stock split took place on March 29, 2016 with a 1:5 split ratio.